Dr. Karl Csaky, Dr. Charles Wykoff, Dr. Jeffrey Heier, 20210408000000
Intravitreal injections with anti-vascular endothelial growth factor (VEGF) agents are associated with significant treatment burden for patients with diabetic macular oedema (DME) and neovascular age-related macular degeneration (nAMD). At the Angiogenesis, Exudation, and Degeneration 2021 Virtual Congress, Dr Karl Csaky of Retina Foundation of the Southwest, Dallas, Texas, US, Dr Charles Wykoff of Retina Consultants of Texas, Houston, Texas, US, and Dr Jeffrey Heier of Ophthalmic Consultants of Boston, Boston, Massachusetts, US, presented results of four phase III trials that compared the efficacy and safety of the investigational bispecific antibody, faricimab, administered at up to Q16W dosing intervals, vs the decoy VEGF-A/placental growth factor (PIGF) receptor aflibercept at Q8W dosing intervals, in patients with retinal vascular diseases.
Roxadustat treatment for anaemia in patients with dialysis-dependent chronic kidney disease (DD CKD) does not come with an increased risk of ophthalmic abnormalities, according to a phase III trial conducted in Japan.
The 2016 Annual Meeting of the American Academy of Ophthalmology (AAO) was held in Chicago, USA, from 15−18 October 2016. A panel of renowned international clinicians in the field of ophthalmology contributed the articles for the Eye on AAO 2016 e-Bulletins, which feature conference highlights, reviews of hot topics discussed at the meeting, Asian and clinical relevance of few of the important topics.